RxDoctor Payments Data

John Duell, MD

Clinical Cardiac Electrophysiology · Dartmouth, MANPI 1598994261

Payments from drug & device makers

$2,760in general payments, 2019–2025

Across 78 payments — averaging $35.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1000
  • Novo Nordisk$261
  • E.r. Squibb & Sons, L.L.C.$249
  • Pfizer$218
  • Boehringer Ingelheim$198
  • Novartis$157
  • plus $677 from 12 others

What the payments were for

  • Travel & lodging$65224%
  • Food & beverage$2,03874%
  • Education$703%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,760 in reported general payments places this provider in the 20th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

See all clinical cardiac electrophysiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$468,468
Medicare patients
1,124
Services billed
6,579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban653$617,722
XareltoRivaroxaban207$247,955
JardianceEmpagliflozin82$51,622
EntrestoSacubitril/Valsartan34$30,588
MultaqDronedarone Hcl26$22,878
Repatha SureclickEvolocumab16$12,746
Metoprolol Succinate603$12,443
Amiodarone Hcl247$11,938
FarxigaDapagliflozin Propanediol21$11,425
Diltiazem 24hr Er (Cd)Diltiazem Hcl110$5,220
Flecainide Acetate79$3,484
Rosuvastatin Calcium75$2,746
Atorvastatin Calcium171$2,332
SotalolSotalol Hcl82$1,767
Amlodipine Besylate203$1,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$218$617,722653 claims
Boehringer IngelheimJardiance$198$51,62282 claims
NovartisEntresto$157$30,58834 claims
AstraZenecaFarxiga$103$11,42521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

Other clinical cardiac electrophysiology in Dartmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →